AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, In Expert Review

  • An expert review of data from 79 real-world studies showed that AstraZeneca plc’s AZN COVID-19 vaccine and the available mRNA COVID-19 vaccines provide equally effective protection against hospitalization and death following two doses.
  • The currently available mRNA vaccines are offered by Moderna Inc MRNA and Pfizer Inc PFEBioNTech SE BNTX.
  • The study shows that Vaxzevria and the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines offer an equivalent degree of protection against hospitalization (91-93%) and death (91-93%), regardless of age.
  • Related: Which COVID-19 Vaccine(s) Significantly Prevented Deaths - Read To Find Out.
  • The data available at the review time relates to the Delta SARS-Cov-2 and earlier variants.
  • Emerging data on third dose boosting from the UK Health Security Agency and Brazil indicates similar findings on serious COVID-19 outcomes resulting from the Omicron variant.
  • AstraZeneca and its global partners have released over three billion vaccine doses to more than 180 countries.
  • Price Action: AZN shares are down 1.68% at $65.60 during the premarket session on the last check Wednesday.
  • Image by Paul McManus from Pixabay
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareTop StoriesGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!